UBA1 and VEXAS syndrome: In a VEXAS syndrome model using a myeloid cell line engineered with a UBA1 Met41euL mutation, TAK-243 treatment led to preferential apoptosis and loss of the UBA1-mutant cells compared to wild-type, indicating that reduced UBA1 activity renders cells uniquely vulnerable to UBA1 inhibition (71).